Pembrolizumab Improves Event-Free Survival in Early NSCLC

TUESDAY, Feb. 13, 2024 -- For patients with early-stage non-small cell lung cancer (NSCLC), event-free survival (EFS) is improved with neoadjuvant pembrolizumab and chemotherapy, according to a study presented at the annual meeting of The Society of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news